Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7152W HIGH $3.06
Volume
1.23 M
Value Traded
2.03 M
Short % Float
15.04%
-1.85%Week
-27.14%1 Month
-40.23%3 Month
-61.75%6 Month
-74.91%5 Year
-90.97%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
95.24 M
EPS (TTM)
-0.67
P/E Ratio
-
Ent. Value
-16.16 M
Total Shares
124.53 M
Float Shares
122.10 M
Insiders
1.92%
Institutions
39.75%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MIST Catalyst Timeline
Dated clinical, regulatory and corporate events for Milestone Pharmaceuticals Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Milestone Pharmaceuticals Inc.
202Total events
11Upcoming
62Tier-1 (high impact)
2019 to 2036Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment UpdateEtripamilApprovedTrial
First European patient enrolled in ReVeRA-301 Phase 3 trial in the Netherlands
atrial fibrillation with rapid ventricular rate (AFib-RVR)source ↗
▲First Patient DosedEtripamilApprovedTrial
Montreal Heart Institute enrolls first Canadian patient in ReVeRA-301 Phase 3 trial
atrial fibrillation with rapid ventricular rate (AFib-RVR)source ↗
▲NMPA NDA ApprovalEtripamilApprovedEx-US Regulatory
NMPA approval of etripamil nasal spray for PSVT in China
paroxysmal supraventricular tachycardia (PSVT)source ↗
▲Milestone PaymentEtripamilApprovedCorporate
Milestone payment of $2.0 million triggered by NMPA approval
●Trial InitiationEtripamilApprovedTrial
Montreal Heart Institute activated as first Canadian clinical trial site for ReVeRA-301
atrial fibrillation with rapid ventricular rate (AFib-RVR)source ↗
◆Poster PresentationPresentation
ePoster presentation on impact of PSVT on daily life and QoL between episodes at ESC Congress 2026
paroxysmal supraventricular tachycardia (PSVT)source ↗
▲First Patient DosedEtripamilApprovedTrial
First patient enrolled in Phase 3 ReVeRA-301 trial of etripamil for AFib-RVR
atrial fibrillation with rapid ventricular rate (AFib-RVR)source ↗
▲Trial InitiationEtripamilApprovedTrial
Initiation of Phase 3 ReVeRA-301 trial
atrial fibrillation with rapid ventricular rate (AFib-RVR)source ↗
●Enrollment UpdateEtripamilApprovedTrial
Enrollment ongoing in Phase 3 ReVeRA-301 trial
atrial fibrillation with rapid ventricular rate (AFib-RVR)source ↗
▲Trial InitiationEtripamilApprovedTrial
First clinical sites activated for Phase 3 registrational trial of etripamil for AFib-RVR
atrial fibrillation with rapid ventricular rate (AFib-RVR)source ↗
▲Enrollment UpdateEtripamilApprovedTrial
US enrollment in ReVeRA-301 commenced
atrial fibrillation with rapid ventricular rate (AFib-RVR)source ↗
◆Oral PresentationPresentation
Presentation at H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
▲Other Regulator MilestoneEtripamilApprovedEx-US Regulatory
EMA MAA accepted for review
paroxysmal supraventricular tachycardia (PSVT)source ↗
▲Trial InitiationEtripamilApprovedTrial
Phase 3 registrational program in AFib-RVR initiated
atrial fibrillation with rapid ventricular rate (AFib-RVR)source ↗
●Poster PresentationEtripamilApprovedPresentation
Details on RESET-PSVT registry presented at PCNA 2026
paroxysmal supraventricular tachycardia (PSVT)source ↗
●Oral PresentationEtripamilApprovedPresentation
Reduction in Health Care Utilization presentation at Stanford BioDesign
paroxysmal supraventricular tachycardia (PSVT)source ↗
◆Oral PresentationPresentation
Management to present at 25th Annual Needham Virtual Healthcare Conference
●Poster PresentationCARDAMYSTApprovedPresentation
Poster presentation at ACC Annual Scientific Session: Minimal Blood Pressure Effects of Intranasal Etripamil for PSVT
PSVTsource ↗
▲EU MAA SubmissionEtripamilApprovedEx-US Regulatory
MAA for etripamil nasal spray in PSVT accepted by EMA
PSVTsource ↗
▲Partnership / LicenseCARDAMYSTApprovedCorporate
Everest Medicines acquires rights from Corxel for Greater China
paroxysmal supraventricular tachycardia (PSVT)source ↗
▲Product LaunchCARDAMYSTApprovedPost-Market
Launch of CARDAMYST nasal spray
paroxysmal supraventricular tachycardia (PSVT)source ↗
●Management ChangeCorporate
David Sandoval appointed as General Counsel and Chief Compliance Officer
▲Product LaunchCARDAMYSTApprovedPost-Market
National sales force deployment
paroxysmal supraventricular tachycardia (PSVT)source ↗
▲Product LaunchCARDAMYSTApprovedPost-Market
CARDAMYST now available through U.S. retail pharmacies
paroxysmal supraventricular tachycardia (PSVT)source ↗
▲Equity OfferingCorporate
$75 million payment received from RTW under Royalty Purchase Agreement
▲EU MAA SubmissionEtripamilApprovedEx-US Regulatory
EMA accepts MAA for etripamil nasal spray in PSVT
paroxysmal supraventricular tachycardia (PSVT)source ↗
▲Product LaunchCARDAMYSTApprovedPost-Market
CARDAMYST became broadly available through retail pharmacies in the US
PSVTsource ↗
▲FDA ApprovalCARDAMYSTApprovedFDA Decision
FDA approval of CARDAMYST for conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults
paroxysmal supraventricular tachycardia (PSVT)source ↗
◆PDUFA DateCARDAMYSTApprovedRegulatory Filing
PDUFA target date for CARDAMYST (etripamil nasal spray) NDA
paroxysmal supraventricular tachycardia (PSVT)source ↗
▲FDA ApprovalCARDAMYSTApprovedFDA Decision
FDA approval of CARDAMYST for PSVT
paroxysmal supraventricular tachycardia (PSVT)source ↗
◆Debt Royalty FinancingCorporate
$75 million royalty purchase agreement payment from RTW extended through end of 2025
◆Poster PresentationEtripamilApprovedPresentation
Poster presentation of combined efficacy, safety, and test dose tolerability of etripamil for acute PSVT across multiple clinical trials at AHA Scientific Sessions 2025
paroxysmal supraventricular tachycardia (PSVT)source ↗
◆Poster PresentationEtripamilApprovedPresentation
Poster presentation at AHA 2025 on combined efficacy, safety, and test dose tolerability of etripamil for acute PSVT
paroxysmal supraventricular tachycardiasource ↗
●NDA SubmissionEtripamilApprovedRegulatory Filing
NDA submitted to FDA for etripamil for PSVT
paroxysmal supraventricular tachycardia (PSVT)source ↗
●NDA SubmissionEtripamilApprovedRegulatory Filing
NDA submitted to FDA for etripamil for PSVT
paroxysmal supraventricular tachycardiasource ↗
◆Oral PresentationPresentation
Corporate update at H.C. Wainwright 27th Annual Global Investment Conference
▲Partnership / LicenseCorporate
Amended royalty purchase agreement providing $75 million upon FDA approval
●NDA SubmissionEtripamilApprovedRegulatory Filing
NDA submitted to FDA for etripamil for PSVT
paroxysmal supraventricular tachycardia (PSVT)source ↗
▲FDA Filing AcceptedCARDAMYSTApprovedRegulatory Filing
FDA accepted response to CRL for CARDAMYST (etripamil) Nasal Spray
PSVTsource ↗
◆PDUFA DateCARDAMYSTApprovedRegulatory Filing
PDUFA date to be determined within 30 days of resubmission acceptance
paroxysmal supraventricular tachycardia (PSVT)source ↗
▼Equity OfferingCorporate
Pricing of $52.5 million public offering of common shares, pre-funded warrants, Series A and Series B common warrants
●NDA SubmissionEtripamilApprovedRegulatory Filing
Milestone recently submitted an NDA to the FDA for etripamil for PSVT
paroxysmal supraventricular tachycardia (PSVT)source ↗
▲FDA Filing AcceptedCARDAMYSTApprovedRegulatory Filing
FDA accepts for review response to CRL for CARDAMYST (etripamil) nasal spray
paroxysmal supraventricular tachycardia (PSVT)source ↗
Past FDA Catalysts and PDUFA Decisions
How MIST actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-12 | CARDAMYST™ (etripamil) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D37 / 100
Pipeline Score
$83M
Pipeline Value
$1M
Commercial Value
Fair Value
Valuation Signal
1
Drugs Scored
0.9x
rNPV / MCap
Top 49%
Micro Cap(rank 324 of 660)
Percentile Rank
Milestone Pharmaceuticals Inc. faces pipeline headwinds (37/100), with $332M risk-adjusted pipeline value, led by Etripamil in Atrial Fibrillation (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $0.8M x 1.0 = $1M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| CARDAMYST | $1M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Etripamil Small moleculeNCT04467905 | Atrial Fibrillation | Phase 3 | COMPLETED | 819 | Aug 10, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every MIST program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| paroxysmal supraventricular tachycardia (PSVT) | 2026-08-27 | Approximately two in three patients adjusted their lifestyle between episodes to avoid stress; nearly 40% reduced their activity or exercise routine because of PSVT; 73% of patients reported daytime activity interruption between PSVT episodes; Automobile driving (53%) and travel (43%) were the everyday activities for which avoidance between PSVT episodes was most frequently rated as bothersome or extremely bothersome (score of 6 or 7 on a 7-point scale); Patients reported an average anxiety level of 3.1 on a 7-point scale; 26% of patients reported feeling extremely anxious at some point during the study; 16% reported the maximum anxiety score at least once; Fatigue and weakness were each rated as bothersome or extremely bothersome (6 or 7 on a 7-point scale) by 65% of patients; Sleep (30%) and capacity for work (22%) were the most commonly reported areas of lifestyle dissatisfaction (score of 1 or 2 on a 5-point scale)Read More | Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between EpisodesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Oliveto JosephDirector, Officer (President and CEO) | Sell | -36,500 446,244 held | $2.26 | 04/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MIST
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.1 % | 10.50 M | 7.83 M | 23.73% ( 1.50 M) |
MIST Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MIST ranks across every disease it competes in
Competitive Position is a premium feature
See how MIST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMIST News
MIST▲ +7.4%on this news
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
Milestone Pharmaceuticals has announced the enrollment of the first European participant in the ReVeRA-301 Phase 3 clinical trial, which is assessing etripamil nasal spray for atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial aims to enroll approximately 150 patients and evaluates the same dosing regimen approved for paroxysmal supraventricular tachycardia. This milestone reflects progress in the global execution of the trial, with enrollment also ongoing in the U.S. and Canada.
Read more →MIST▼ -7.8%on this news
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Milestone Pharmaceuticals has successfully enrolled the first Canadian participant in the ReVeRA-301 Phase 3 trial, which evaluates etripamil nasal spray for treating atrial fibrillation with rapid ventricular rate (AFib-RVR). This trial aims to enroll 150 patients and follows promising Phase 2 results. The Montreal Heart Institute is the first Canadian site activated for this multinational study.
Read more →MISTMilestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
Milestone Pharmaceuticals has received approval from China's NMPA for etripamil nasal spray to treat paroxysmal supraventricular tachycardia (PSVT), marking its first regulatory approval outside the U.S. The approval is based on successful Phase 3 study results and will enable Everest Medicines to commercialize the product in Greater China. This milestone also triggers a $2 million payment to Milestone.
Read more →MISTMilestone Pharmaceuticals to Present at Upcoming Investor Conferences
Milestone Pharmaceuticals has announced its participation in upcoming investor conferences. The company is focused on developing innovative cardiovascular treatments, including its lead product, CARDAMYST (etripamil) nasal spray, which is FDA-approved for treating certain heart conditions. Webcasts of the presentations will be available on their website for 90 days post-event.
Read more →MISTMilestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
Milestone Pharmaceuticals presented findings from a longitudinal study at the ESC Congress 2026, revealing how paroxysmal supraventricular tachycardia (PSVT) affects patients' daily lives and quality of life between episodes. The study showed that many patients adjust their lifestyles to avoid stress, with significant anxiety and activity interruptions reported. The results highlight the need for improved treatment options to address the ongoing burden of PSVT.
Read more →MISTMilestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
Milestone Pharmaceuticals has initiated the Phase 3 ReVeRA-301 trial for etripamil nasal spray, targeting atrial fibrillation with rapid ventricular rate (AFib-RVR). This trial builds on positive Phase 2 results, aiming to validate a self-administered treatment option that could alleviate the burden on emergency services. The study will evaluate the efficacy of etripamil in reducing ventricular rates and improving patient-reported symptoms.
Read more →MIST▼ -11.4%on this news
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Milestone Pharmaceuticals reported a positive corporate update, highlighting that over 50% of commercially insured lives in the U.S. now have coverage for their CARDAMYST nasal spray. This marks a significant increase in coverage for the Phase 3 registrational trial of etripamil for treating atrial fibrillation with rapid ventricular rate. Additionally, the activation of the first clinical sites is a notable advancement for the trial.
Read more →MISTMilestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
Milestone Pharmaceuticals Inc. will announce its second quarter financial results for 2026 on August 12. The announcement will include a business update and will be followed by a conference call for investors. The company focuses on innovative cardiovascular medicines, with its lead product, CARDAMYST™, already FDA-approved.
Read more →MISTMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals has granted 288,000 equity options to six new employees as part of its 2021 Inducement Plan. The options have a grant date of July 1, 2026, with an exercise price of $1.32 per share. The shares will vest over four years, contingent on the employees' continuous service. This grant aligns with Nasdaq Listing Rule 5635(c)(4), aimed at incentivizing new hires.
Read more →MIST▼ -5.2%on this news· ran to -17% by day 3
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Milestone Pharmaceuticals Inc. will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The presentation will include a live webcast available for 90 days after the event. Milestone is known for its innovative cardiovascular medicines, including the FDA-approved CARDAMYST™ nasal spray.
Read more →MIST▼ -9.5%on this news· ran to -23% by day 3shared move
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
Milestone Pharmaceuticals reported positive first quarter 2026 results, highlighting strong early adoption of its CARDAMYST nasal spray for PSVT. The company secured national formulary coverage with Express Scripts and initiated a Phase 3 trial for Atrial Fibrillation-RVR. Despite a net loss of $26.1 million, Milestone maintains a solid cash position to support ongoing operations.
Read more →MISTMilestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
Milestone Pharmaceuticals Inc. will announce its financial results for Q1 2026 on May 13, 2026, before market opening. The announcement will be accompanied by a conference call and webcast for investors at 8:30 AM ET. The company focuses on innovative cardiovascular treatments, including its FDA-approved product CARDAMYST™.
Read more →MIST▲ +5.9%on this news· ran to +33% by day 3
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Milestone Pharmaceuticals Inc. will present at the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. The presentation is scheduled for April 13 at 3:45 PM EDT, with a webcast available for viewing. The company focuses on innovative cardiovascular medicines, including its FDA-approved product, CARDAMYST™.
Read more →MIST▼ -20%on this news
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT
Milestone Pharmaceuticals reported strong financial results for Q4 and full year 2025, highlighted by the FDA approval of CARDAMYST, a nasal spray for PSVT. The product's launch is on track with positive early engagement from healthcare providers. The company also plans to expand its indications for etripamil, including a Phase 3 program for AFib-RVR.
Read more →MISTMilestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
Milestone Pharmaceuticals Inc. will announce its fourth quarter and full-year 2025 financial results on March 20, 2026. The announcement will precede a conference call and webcast for investors at 8:30 AM ET. The company is known for its innovative cardiovascular medicines, including the FDA-approved CARDAMYST™ nasal spray.
Read more →MISTMilestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
Milestone Pharmaceuticals announced that key executives will present at the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, in Boston. The presentation will be available via webcast on March 3 at 9:10 AM EST, with a replay accessible for 90 days. The company focuses on innovative cardiovascular treatments, including its FDA-approved product, CARDAMYST™.
Read more →MISTMilestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
Milestone Pharmaceuticals has appointed David Sandoval as General Counsel and Chief Compliance Officer. His extensive experience in legal and compliance within the life sciences sector will support the launch of CARDAMYST, the first self-administered treatment for PSVT. Sandoval aims to enhance the company's legal framework and drive shareholder value.
Read more →MISTMilestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Milestone Pharmaceuticals has announced the U.S. availability of CARDAMYST (etripamil) nasal spray, the first FDA-approved self-administered treatment for adults with paroxysmal supraventricular tachycardia (PSVT). The product aims to provide patients with a convenient option for managing acute episodes of PSVT. A national sales force will support its launch, and the company is negotiating with insurers to ensure affordability and coverage.
Read more →About Milestone Pharmaceuticals Inc.
Headquarters1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, A8, H4M 2X6
BIOPHARMAWATCH ELITE PLUS
Trade the next MIST catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime